Related Experiment Video
Updated: Sep 6, 2025
Rapid Depletion of Renal Macrophages using Human CD59/Intermedilysin Cell Ablation Tool
Published on: May 9, 2025
Inhibition of imrecoxib on mRNA and protein expression of CYP2C11 enzyme in rats
1Department of Pharmacy, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Abstract:
To evaluate the effect of imrecoxib on CYP2C11 enzyme activity, mRNA, and protein expression, a UPLC method was established. Tolbutamide was selected as the CYP2C11 enzyme-specific probe drug and incubated with imrecoxib in rat liver microsomes. The yield of 4-hydroxytolbutamide was measured using UPLC to investigate the effect of imrecoxib on CYP2C11 enzyme activity. Imrecoxib (10 mg/kg) was administered intragastrically twice daily. After 1, 7, and 14 days of administration, the liver tissues were analyzed. The expression of CYP2C11 enzyme mRNA was determined using reverse transcription-polymerase chain reaction, and its protein expression was determined using Western blot analysis. Imrecoxib concentration was inversely proportional to the production of 4-hydroxytolbutamide in liver microsomes. Imrecoxib demonstrated a dose-dependent inhibitory effect on CYP2C11 activity with IC50 = 74.77 μM. After administration, reverse transcription-polymerase chain reaction showed CYP2C11 enzyme mRNA expressions were 65% (P < 0.05), 35%, and 34% of the control group, respectively (P < 0.01). Western blot analysis showed CYP2C11 enzyme protein expressions were 80, 37, and 34% of the control group, respectively (P < 0.01). Imrecoxib can reduce mRNA and protein expression of CYP2C11 enzyme in rat liver and inhibit the activity of CYP2C11 enzyme in a dose-dependent manner. However, it does not produce clinically significant drug interactions.
Insights
Imrecoxib inhibits rat CYP2C11 enzyme activity, mRNA, and protein expression in a dose-dependent manner. Despite these effects, imrecoxib does not appear to cause clinically significant drug interactions.
Area of Science:
- Pharmacology
- Biochemistry
- Drug Metabolism
Background:
- Cytochrome P450 enzymes, particularly CYP2C11, play a crucial role in drug metabolism.
- Understanding the impact of novel compounds like imrecoxib on CYP enzyme activity is essential for predicting potential drug-drug interactions.
Purpose of the Study:
- To investigate the effects of imrecoxib on the activity, mRNA, and protein expression of the CYP2C11 enzyme in rat liver.
- To determine if imrecoxib causes clinically significant drug interactions through its effect on CYP2C11.
Main Methods:
- A UPLC method was developed to measure 4-hydroxytolbutamide, a metabolite of the CYP2C11-specific probe drug tolbutamide.
- Imrecoxib's inhibitory effect on CYP2C11 activity was assessed in rat liver microsomes.
- mRNA and protein expression levels of CYP2C11 were analyzed using RT-PCR and Western blot after in vivo administration of imrecoxib.
Main Results:
- Imrecoxib demonstrated a dose-dependent inhibition of CYP2C11 activity with an IC50 of 74.77 μM.
- In vivo administration of imrecoxib significantly reduced CYP2C11 mRNA and protein expression in a time- and dose-dependent manner.
- Despite significant inhibition of enzyme activity and expression, imrecoxib did not lead to clinically significant drug interactions.
Conclusions:
- Imrecoxib inhibits CYP2C11 enzyme activity, mRNA, and protein expression in rats.
- The observed effects of imrecoxib on CYP2C11 are dose-dependent.
- Imrecoxib is unlikely to cause clinically significant drug interactions related to CYP2C11-mediated metabolism.
More Related Videos
10:51Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 15, 2013
05:28Monitoring On-Target Signaling Responses in Larval Zebrafish - Z-REX Unmasks Precise Mechanisms of Electrophilic Drugs and Metabolites
Published on: June 2, 2023
Related Concept Videos
02:15Experimental RNAi
01:31Regulation of the Unfolded Protein Response